https://pharmaphorum.com/ en Wed, 23 Apr 2025 15:49:08 +0000 Wed, 23 Apr 2025 13:20:40 +0000 https://pharmaphorum.com/news/roche-gets-eu-okay-chest-pain-algorithm Roche has claimed a CE Mark in the EU for an AI algorithm that can help doctors decide whether patients with chest pain are having a heart attack. Phil.Taylor https://pharmaphorum.com/news/roche-gets-eu-okay-chest-pain-algorithm 2025-04-23T13:20:40+0000 Feed - News and features https://pharmaphorum.com/news/axtria-unveils-transformational-agentic-ai-platform-life-sciences Axtria today announced its next generation of Axtria InsightsMAx for life sciences, powered by agentic AI. Nicole.Raleigh https://pharmaphorum.com/news/axtria-unveils-transformational-agentic-ai-platform-life-sciences 2025-04-23T12:30:00+0000 Feed - News and features https://pharmaphorum.com/news/first-drug-rare-disease-apds-cleared-nhs-use Pharming's Joenja has become the first disease-modifying drug that can be used by the NHS to treat APDS, an ultra-rare immunodeficiency disorder. Phil.Taylor https://pharmaphorum.com/news/first-drug-rare-disease-apds-cleared-nhs-use 2025-04-23T12:21:16+0000 Feed - News and features https://pharmaphorum.com/news/swiss-biotech-veraxa-vaults-nasdaq-listing-spac-deal Cancer drug developer Veraxa Biotech has reached a deal to merge with a SPAC in a deal that will give it a Nasdaq listing and a $1.6bn-plus valuation. Phil.Taylor https://pharmaphorum.com/news/swiss-biotech-veraxa-vaults-nasdaq-listing-spac-deal 2025-04-23T11:24:54+0000 Feed - News and features https://pharmaphorum.com/news/has-trial-result-burst-bms-cobenfy-bubble Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a failed clinical trial. Phil.Taylor https://pharmaphorum.com/news/has-trial-result-burst-bms-cobenfy-bubble 2025-04-23T10:07:18+0000 Feed - News and features